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Dissertation Research Grants for Underrepresented
Minorities in the Ethical, Legal, and Social
Implications (ELSI) of Genetics Research
This PA is meant to stimulate and encourage under-
represented minority doctoral candidates from a
variety of academic disciplines and programs to con-
duct research related to the ethical, legal, and social
implications (ELSI) of genetics, genomics, and
gene–environment interaction research. It is hoped
that this program will facilitate the entry of promis-
ing new minority investigators into the field of ELSI
research.
The usual mechanisms used for the support of
doctoral dissertation research have not attracted sig-
nificant numbers of underrepresented minority stu-
dents to the field of ELSI research. The intent of
these dissertation research grants is to attract larger
numbers of underrepresented minority students as
ELSI investigators and to assist in providing a posi-
tive and constructive research experience that will
stimulate them to pursue research careers in this field.
Applications may be made for support of
research in any area relevant to the ethical, legal, or
social implications of genetic and genomic research.
Proposed projects can range from large clinical studies
of the impact of genetic information and technologies
in health care settings to smaller analytical studies of
how this information affects individuals or how com-
munities view themselves or are viewed by others.
General areas of programmatic interest are set
out on the National Human Genome Research
Institute (NHGRI) Division of Extramural Research
Web site at http://www.nhgri.nih.gov:80/
About_NHGRI/Der/Elsi/. The following five specific
research goals have been developed for the NHGRI
ELSI program through the year 2003 (a list of exam-
ples of research questions associated with each of these
goals is available online at http://www.nhgri.nih.
gov:80/98plan/elsi/): 1) examine the issues surround-
ing the completion of the human DNA sequence and
the study of human genetic variation; 2) examine
issues raised by the integration of genetic technologies
and information into health care and public health
activities; 3) examine issues raised by the integration
of knowledge about genomics and gene–environment
interactions into nonclinical settings; 4) explore ways
in which new genetic knowledge may interact with a
variety of philosophical, theological, and ethical per-
spectives; and 5) explore how the social environment,
including socioeconomic factors, age, gender, and
concepts of race and ethnicity, influences the use,
understanding, and interpretation of genetic informa-
tion, the utilization of genetic services, and the devel-
opment of policy.
Each of the sponsoring institutes has a particular
interest in ELSI research relevant to its own mission.
The NIEHS is particularly interested in understand-
ing the impact of environmental exposures on
human health and disease. The NIEHS expanded its
research program on genetic susceptibility to envi-
ronmentally associated diseases through the
Environmental Genome Project. Understanding
genetic susceptibility to environmental agents will
allow more precise identification of the environmen-
tal agents that cause disease and the true risks of
exposures. This can lead to more effective disease
prevention and improved public health. Further
information on the Environmental Genome Project
can be found at http://www.niehs.nih.gov/
envgenom/home.htm.
The applicant must be a full-time student in
good standing enrolled in an accredited doctoral
degree program in a relevant social science or
humanities discipline, such as anthropology, eco-
nomics, health policy, public health, history, philos-
ophy, political science, psychology, religious studies,
or sociology. The applicant must be conducting or
intending to conduct research in one of the areas
described in this PA. The applicant must have
obtained approval of the dissertation proposal by the
dissertation committee by the time of application.
All requirements for the doctoral degree other than
the dissertation (and clinical internship, if applica-
ble) must also be completed by the time of applica-
tion. The applicant’s eligibility must be verified in a
letter of certification from the mentor (the chair of
the dissertation committee or other academic advi-
sor) and submitted with the grant application.
Priority will be given to applicants who belong
to ethnic or racial groups that are currently under-
represented in ELSI research. Within these groups,
persons with disabilities are particularly encouraged
to apply. Academic institutions are encouraged to
facilitate applications from qualified applicants.
This PA will use the NIH small grant (R03)
award mechanism. Applicants will be solely respon-
sible for planning, directing, and executing the pro-
posed project. Grants to support dissertation
research will provide no more than $25,000 (one
module) in direct costs. An application that exceeds
this limit will be returned to the applicant without
review. Grants are normally awarded for 12 months,
but may be extended without additional funds for
up to a total of 24 months. More information on
this PA is available online at http://grants.nih.gov/
grants/guide/pa-files/PA-02-048.html. 
Contact: Jean E. McEwen, ELSI Research
Program, NHGRI, Building 31, Room B2B07, 31
Center Drive, MSC 2033, Bethesda, MD 20892-
2033 USA, 301-402-4997, fax: 301-402-1950, e-
mail: jm522n@nih.gov; James A. Lipton, Division of
Population and Health Promotion Sciences, National
Institute of Dental and Craniofacial Research,
Building 45, Room 4AS-37J, Bethesda, MD 20892-
6402 USA, 301-594-2618, fax: 301-480-8318, e-
mail: James_Lipton@nih.gov; Shobha Srinivasan,
Chemical Exposures and Molecular Biology Branch,
Division of Extramural Research and Training,
NIEHS, MD EC-21, PO Box 12233, 111 T. W.
Alexander Drive, Research Triangle Park, NC 27709
USA, 919-541-2506, fax: 919-316-4606, e-mail:
sriniva2@niehs.nih.gov; Jennifer Harris, Behavioral
and Social Research Program, National Institute on
Aging, 7201 Wisconsin Avenue, Suite 533, MSC
9205, Bethesda, MD 20892-9205 USA, 301-496-
3138, fax: 301-402-0051, e-mail: jh475o@nih.gov;
Jonathan D. Pollock, Division of Neuroscience and
Behavioral Research, National Institute on Drug
Abuse, 6001 Executive Boulevard, Room 4284,
MSC 9555, Bethesda, MD 20892-9555 USA, 301-
443-6300, fax: 301-594-6043, e-mail: jp183r@
nih.gov. Reference: PA No. PA-02-048
Cancer Therapy–Related Use of Genetically
Engineered Mice
The goal of this National Cancer Institute (NCI) PA
is to encourage the use of genetically engineered
mouse cancer models for cancer therapy–related goals.
Mouse cancer-prone models with heritable genetic
alterations are usually derived to explore mechanisms
that underlie basic cancer or tumor biology. Through
in-depth phenotyping, these models are often discov-
ered to have molecular genetic profiles and
histopathology that are similar to the molecular signa-
tures and tumor progression of human malignancies.
Because of the similarities, the models may be appro-
priate to identify molecular targets for therapy or to
test new molecularly targeted agents. The models may
be credentialed with new agents through systematic
preclinical trials to discover how well the mice mimic
either the clinical course of human cancer in response
to therapy or the development of resistance in
response to therapy. The model strains may also be
used to discover the genetic determinants of response
to therapeutic agents. 
This PA is intended to encourage those who
develop genetically engineered mice (GEMs) for stud-
ies of tumor biology to delineate how appropriate
they are for cancer therapy–related research, and to
define the practical limitations to use of GEMs for
preclinical therapy research. Where advisable, the
applicants to this PA should include collaborators
who are expert in fields such as translational research,
clinical trials, imaging research, and statistical analysis.
Applicants are also encouraged to consider subcon-
tracts with companies that can provide relevant ser-
vices that are unavailable at their institutions. 
The following are examples of topics that are
responsive to this PA; however, appropriate subjects
are not limited to the following: 1) preclinical trials of
appropriate agents in relevant GEMs to determine if
the timing and penetrance of the tumor phenotype
limits the value of the model for this use; 2) preclini-
cal trials to credential appropriate GEMs for how well
they reflect the observed clinical course of human can-
cers; 3) appropriate experiments to determine the
pharmacodynamics and pharmacokinetics of specific
agents in GEMs; 4) preclinical trials that incorporate
use of high-throughput technologies or small-animal
imaging to monitor delivery of agents or response to
therapy; 5) preclinical trials to determine efficacy of
new single or multiple agents at different stages of
tumor progression; 6) preclinical trials that examine
which aspects of trial design are appropriate for exper-
iments with GEMs; and 7) examination of GEMs
and their corresponding normal background strains
for genetic determinants of therapeutic response.
This PA will use the NIH R01 award mecha-
nism. Applicants will be solely responsible for plan-
ning, directing, and executing the proposed project.
Applications must be prepared using the PHS 398
research grant application instructions and forms,
available at http://grants.nih.gov/grants/funding/
phs398/phs398.html in an interactive format. The
deadline for receipt of applications is 19 April 2002.
Further information on this PA is available online at
http://grants.nih.gov/grants/guide/pa-files/
PAR-02-051.html.
Contact: Cheryl L. Marks, Division of Cancer
Biology, NCI, Executive Plaza North, Room 5000,
Bethesda, MD 20892-7380 USA, 301-594-8778, fax:
301-496-8656, e-mail: cm74v@nih.gov. Reference:
PA No. PAR-02-051
Airborne Particulate Matter Health Effects:
Cardiovascular Mechanisms 
The U.S. Environmental Protection Agency (EPA)
invites research grant applications to conduct studies
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on the role of particulate matter (PM) air pollution
in cardiovascular illness and mortality. A potentially
important role of PM has been suggested by epi-
demiology studies showing increased cardiopul-
monary-related mortality and hospital admissions
for cardiovascular disease associated with increases in
exposure to PM. The objective of this program is to
encourage in vitro and in vivo research in laboratory
animals and humans on the specific cellular, molecu-
lar, and physiologic mechanisms by which ambient
air PM, alone or in combination with gaseous co-
pollutants, mediates adverse cardiovascular effects. A
subobjective is to encourage involvement of cardio-
vascular experts in research efforts to address the
adverse health effects associated with PM exposure.
Areas of research that would be considered respon-
sive to the RFA include the following: 
1) Mechanisms of pathogenesis: humans and/or lab-
oratory animals: In vitro and in vivo research to devel-
op and evaluate novel hypotheses addressing specific
mechanisms by which PM may affect the cardiovascu-
lar system. These could include, but are not limited
to, factors affecting the electrical activity of the heart
or processes that damage cardiac cells, cause endothe-
lial cell dysfunction, or cause alterations in blood vis-
cosity or clotting. Proposals that address these issues
in an integrated manner applying both cellular and
molecular approaches in either laboratory animals or
humans are encouraged.
2) Models of susceptibility: Epidemiology studies
suggest that elderly people with cardiovascular disease
are particularly susceptible to the effects of PM.
Therefore, proposals are encouraged that use animal
models of cardiovascular disease to study the effects of
PM, especially newer genetic models that target spe-
cific cellular pathways. Specific aims should include
studies elucidating the underlying mechanism of PM
effects in these models. If development of a new ani-
mal model is proposed, the proposal should include
plans to disseminate the model and willingness to
share the model with the scientific community.
3) Controlled exposure studies in humans or ani-
mals: These studies may demonstrate whether and
how inhaled PM directly affects the heart (e.g.,
through uptake of particles into the circulatory system
or through release of soluble substances into the circu-
latory system); whether and how PM affects auto-
nomic control of the heart and cardiovascular system;
or whether and how lung inflammation caused by
PM exposure leads to cardiovascular-related morbidi-
ty (e.g., lung inflammation and cytokine production
cause adverse systemic hemodynamic effects, lung
inflammation from inhaled PM causes increased
blood coagulability, and lung injury from inhaled PM
causes impairment of oxygenation in individuals with
cardiac disease). 
Proposals with a primary emphasis on the pul-
monary effects of PM rather than on how pulmonary
factors interact with the cardiovascular system will not
be considered responsive. Particles that are not con-
sidered environmentally relevant or that are not gen-
erally found in the air in urban areas should not be
proposed for study, nor should particles generally
encountered primarily in occupational settings.
Applications proposing to study the effects of silica or
asbestos will not be considered. 
It is anticipated that a total of approximately
$5 million, including direct and indirect costs, will be
awarded, depending on the availability of funds.
Proposals may request funding for projects with a
total cost up to $350,000/year with a duration of up
to 3 years.
The deadline for final applications is 30 April
2002. A set of special instructions on how applicants
should apply for a National Center for Environ-
mental Research (NCER) grant is found on the
NCER Web site located at http://es.epa.gov/
ncer/rfa/forms/downlf.html under “Standard
Instructions for STAR Grants.” The necessary forms
for submitting an application will be found on this
Web site. Complete information on this announce-
ment is available online at http://es.epa.gov/ncer/
rfa/02pmcardio.html. 
Contact: Stacey Katz, 202-564-8201, e-mail:
katz.stacey@epa.gov; Gail Robarge, 202-564-8301, e-
mail: robarge.gail@epa.gov. E-mail inquiries are pre-
ferred. Reference: 2002-STAR-G1
Valuation of Environmental Impacts on
Children’s Health
The U.S. Environmental Protection Agency (EPA)
Office of Research and Development, National
Center for Environmental Research (NCER), in
cooperation with the EPA Office of Children’s
Health Protection, announces the third year of an
extramural grants competition supporting research
leading to improved valuation of reducing environ-
mental risks to children’s health. 
The EPA has supported similar socioeconomic
research in prior years through the EPA/National
Science Foundation joint program on Decision-
Making and Valuation for Environmental Policy,
and through the 2000 and 2001 Valuation of
Environmental Impacts on Children’s Health solici-
tations. The competition encourages proposals from
researchers from all behavioral, social, and economic
sciences. It encourages collaborations with
non–social science disciplines when needed to
answer important social science questions. It will
support research conducted within a single discipli-
nary tradition, and encourages novel, collaborative,
and interdisciplinary scientific efforts.
To promote research that would enhance eco-
nomic valuation of reducing environmental risks to
children’s health, the EPA requests applications for
research funding to identify willingness to pay (WTP)
for reductions in morbidity and mortality risks to chil-
dren’s health. All proposals should clearly identify the
environmental stressors and resulting health effects
that will be investigated, as well as the attributes of
children (as children and as future adults) that are
altered by those effects. Examples of such attributes
include intelligence, fertility, functionality, mobility,
and life expectancy. Emphasis should be on develop-
ment of empirical research and data. 
This year’s Valuation of Environmental Impacts
on Children’s Health solicitation requests proposals
addressing both acute and chronic threats to chil-
dren’s health. The EPA invites development of WTP
estimates for a variety of health end points including
1) childhood cancers, 2) incidence of food- or water-
borne pathogenic illnesses, 3) developmental disor-
ders, 4) respiratory illnesses, and 5) diseases, both
fatal and nonfatal, that may manifest in adulthood
as a result of childhood exposure to toxicants or
pathogens. Proposals should clearly identify where
outcomes are specific to certain health end points, as
well as where they are specific to the robustness of
results with respect to different health end points. 
Research proposals should address one or both
of the following objectives: 1) development of meth-
ods to measure the value of reducing morbidity and
mortality risks to children’s health using either
established or novel techniques; and/or 2) develop-
ment of empirical estimates of the value of reducing
a specific risk or set of related risks. Applicants are
encouraged to submit proposals that achieve more
than one of these objectives and involve experts from
economics and other disciplines. 
Examples of related research questions include
1) what is the value for reducing fatal risks to chil-
dren, and how does it compare to a similar value for
adults; 2) what is the value of lost school or recre-
ational days, reduced intelligence, or other measures
of avoided child morbidity; 3) what are the roles of
age, dependency, ongoing development, and future
potential of children in affecting how valuation of
potential long-term effects is derived; 4) what is the
role of family structure (e.g., presence or absence of,
or number of, children in household) on the valua-
tion of children’s health; 5) what is the role of altru-
ism—particularly to unrelated children—in how
society values reductions in children’s health risks;
and 6) how should the intergenerational aspects of
risks imposed by the current generation on future
generation(s) be addressed.
The results of this research are expected to
inform federal and state policy makers in both exec-
utive and legislative capacities, as well as members of
regulated communities, the academic community,
and public interest groups, all of whom will be
stakeholders and participants in the debate on uses
of children’s health valuation results.
The EPA anticipates making approximately 4–8
awards totaling about $1–2 million. The projected
range is $50,000–200,000 per award per year, with
durations of 1–3 years. Field experiments, survey
research, and multi-investigator projects may justify
the higher funding level. Awards made through this
competition will depend on the availability of funds.
Requests for amounts in excess of a total of
$400,000 will not be considered.
The deadline for receipt of applications is 8 May
2002. Complete information on this announcement
is available online at http://es.epa.gov/ncer/rfa/
02childrenval.html. A set of special instructions on
how applicants should apply for an NCER grant is
found on the NCER Web site at http://es.epa.gov/
ncer/rfa/forms/downlf.html.
Contact: Matthew Clark, EPA, NCER, 202-
564-6842, fax: 202-565-2447, e-mail: clark.
matthew@epa.gov. E-mail inquiries are preferred.
Reference: 2002-STAR-F1 for Valuation of
Children’s Health
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